Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
These timelines reflect population averages from controlled trials
Amivantamab, the bispecific EGFRMET antibody already approved for EGFR exon 20 insertionpositive NSCLC, continues to be evaluated in ongoing clinical trials (NCT04077463)
Tirzepatide Tirzepatide is a dual GLP-1 and GIP receptor agonist designed to target multiple metabolic pathways
GLP-1Ra at doses intended for T2D management Studies have examined the risk of fracture in both obese and non-obese individuals taking GLP-1Ra at doses intended for T2D (such as liraglutide 1.2 mg daily versus 3.0 mg daily for obesity) [75,76,77]
US$ 24.70
US$ 26.86
US$ 26.00
US$ 28.35
